Paid Clinical Trials in Goodyear, AZ
As of July 2026, 42 paid clinical trials are recruiting in Goodyear, Arizona. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Goodyear offers studies at sites including CTCA at Western Regional Medical Center for conditions such as Breast Cancer, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Metastatic Castration-Resistant Prostate Cancer. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Goodyear
Trials by drug in Goodyear
Filter results
41 clinical trials
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
A Study of BG-C477 in Participants With Advanced Solid Tumors
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Top Research Study Locations in Goodyear
Researchers run research studies in Goodyear, AZ at 20 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| CTCA at Western Regional Medical Center | AL Amyloidosis, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 12 |
| Ironwood Cancer & Research Centers | Advanced Non-Small Cell Lung Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung | 5 |
| City of Hope - Phoenix | Hematologic Malignancies, KRAS G12C Lung Cancer, Non-Small Cell Lung Cancer | 3 |
| City of Hope Cancer Center Phoenix | Extensive Stage Small-cell Lung Cancer, Metastatic Castration-resistant Prostate Cancer, Small-cell Lung Cancer | 2 |
| City of Hope Phoenix | Carcinoma, Non-Small-Cell Lung, Hodgkin Lymphoma, Lymphoma | 2 |
| City of Hope Phoenix Cancer Center | Advanced Solid Tumors, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors | 2 |
| Cancer Treatment Center of America Phoenix | Leukemia, Myeloid, Acute | 1 |
| Cancer Treatment Centers of America, Phoenix | Advanced/Metastatic Non-Small Cell Lung Cancer | 1 |
| City of Hope | Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Cancer | 1 |
| City of Hope - Cancer Center Phoenix | Breast Cancer | 1 |
| Clinical Study Site | Metastatic Colorectal Cancer (CRC) | 1 |
| GSK Investigational Site | Myelodysplastic Syndromes | 1 |
| I-Mab | Advanced Cancer, Esophageal Adenocarcinoma, Gastric Cancer | 1 |
| Investigative | Advanced Solid Tumor, Breast Cancer, Homologous Recombination Deficiency | 1 |
| Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers | Cancer of the Prostate, Hormone Sensitive Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC) | 1 |
| Local Institution - 007-556-A | Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | 1 |
| Western Reg MC-COH Phoenix | Early Breast Cancer | 1 |
| Western Regional Medical Center - City of Hope Phoenix Goodyear | Metastatic Castration-Resistant Prostate Cancer | 1 |
| Western Regional Medical Center, Inc. dba. City of Hope Phoenix | Multiple Myeloma | 1 |
| Western Regional Medical Center, LLC | Metastatic Non-small Cell Lung Cancer | 1 |
Active & Upcoming Studies in Goodyear (2026)
Recruiting trials in Goodyear grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (36 active studies)
- Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3 · Phase 2 · City of Hope Medical Center
- Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial · Phase 3 · City of Hope Medical Center
Common conditions studied in Goodyear
- Breast Cancer (3 active studies)
- Advanced Non-Small Cell Lung Cancer (2 active studies)
- Carcinoma, Non-Small-Cell Lung (2 active studies)
- Metastatic Castration-Resistant Prostate Cancer (2 active studies)
- Multiple Myeloma (2 active studies)
- Non-Small Cell Lung Cancer (2 active studies)
Leading research sponsors in Goodyear
- Pfizer
- City of Hope Medical Center
- Amgen
- BeOne Medicines
- Janssen Research & Development, LLC
Frequently asked questions
How many paid clinical trials are currently recruiting in Goodyear?
There are approximately 42 recruiting clinical trials in Goodyear, Arizona listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Goodyear pay participants?
Most recruiting trials in Goodyear compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Goodyear?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Goodyear?
The most common conditions under active study in Goodyear include Breast Cancer (3), Advanced Non-Small Cell Lung Cancer (2), Carcinoma, Non-Small-Cell Lung (2), Metastatic Castration-Resistant Prostate Cancer (2), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Goodyear?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Goodyear on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Goodyear?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Goodyear?
Recruiting research sites in Goodyear include CTCA at Western Regional Medical Center, Ironwood Cancer & Research Centers, City of Hope - Phoenix, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Goodyear right now?
The largest active categories in Goodyear are Cancer & tumors (36). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.